Form 8-K - Current report:
SEC Accession No. 0001213900-22-021411
Filing Date
2022-04-25
Accepted
2022-04-25 16:40:17
Documents
13
Period of Report
2022-04-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea158792-8k_nektarthera.htm   iXBRL 8-K 34479
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS ANNOUNCES STRATEGIC REORGANIZATION PLA ea158792ex99-1_nektarther.htm EX-99.1 22561
  Complete submission text file 0001213900-22-021411.txt   239636

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE nktr-20220425.xsd EX-101.SCH 3027
4 XBRL LABEL FILE nktr-20220425_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE nktr-20220425_pre.xml EX-101.PRE 22591
7 EXTRACTED XBRL INSTANCE DOCUMENT ea158792-8k_nektarthera_htm.xml XML 3491
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 22850182
SIC: 2834 Pharmaceutical Preparations